{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T12:42:40Z","timestamp":1793796160534,"version":"4.6.1"},"reference-count":67,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T00:00:00Z","timestamp":1757894400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T00:00:00Z","timestamp":1757894400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100000024","name":"Gouvernement du Canada | Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["FDN-154307"],"award-info":[{"award-number":["FDN-154307"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100016067","name":"Fondation Charles-Bruneau","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100016067","id-type":"DOI","asserted-by":"crossref"}]},{"name":"The Everest Centre for Low-grade Paediatric Brain Tumours"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Immunol"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1038\/s41590-025-02268-7","type":"journal-article","created":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T09:04:04Z","timestamp":1757927044000},"page":"1794-1806","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["A spatial map of MAPK-activated immunosuppressive myeloid populations in pediatric low-grade glioma"],"prefix":"10.1038","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5866-0501","authenticated-orcid":false,"given":"Augusto Faria","family":"Andrade","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8600-8876","authenticated-orcid":false,"given":"Romain","family":"Sigaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8449-9221","authenticated-orcid":false,"given":"Evan","family":"Puligandla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bridget","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elham","family":"Karimi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3258-4296","authenticated-orcid":false,"given":"Alva","family":"Annett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morteza","family":"Rezanejad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2724-6401","authenticated-orcid":false,"given":"Wajih","family":"Jawhar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-7350-5681","authenticated-orcid":false,"given":"Yi","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone","family":"Schmid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Selt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pablo","family":"Hern\u00e1iz Driever","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Svea","family":"Horn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3237-6021","authenticated-orcid":false,"given":"Philipp","family":"Sievers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0349-1955","authenticated-orcid":false,"given":"Marco","family":"Prinz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7720-8817","authenticated-orcid":false,"given":"Markus","family":"Glatzel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Mawrin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Hartmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camelia-Maria","family":"Monoranu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4804-5497","authenticated-orcid":false,"given":"Liza","family":"Konnikova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5441-1962","authenticated-orcid":false,"given":"Felix","family":"Sahm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5447-5322","authenticated-orcid":false,"given":"Stefan M.","family":"Pfister","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olaf","family":"Witt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David T. W.","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arend","family":"Koch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia L.","family":"Kleinman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Capper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8771-2577","authenticated-orcid":false,"given":"Logan","family":"Walsh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2485-3692","authenticated-orcid":false,"given":"Nada","family":"Jabado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7267-1052","authenticated-orcid":false,"given":"Till","family":"Milde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,15]]},"reference":[{"key":"2268_CR1","doi-asserted-by":"crossref","first-page":"iv1","DOI":"10.1093\/neuonc\/noad149","volume":"25","author":"QT Ostrom","year":"2023","unstructured":"Ostrom, Q. T. et al. CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2016\u20132020. Neuro. Oncol. 25, iv1\u2013iv99 (2023).","journal-title":"Neuro. Oncol."},{"key":"2268_CR2","doi-asserted-by":"crossref","first-page":"8673","DOI":"10.1158\/0008-5472.CAN-08-2097","volume":"68","author":"DT Jones","year":"2008","unstructured":"Jones, D. T. et al. Tandem duplication producing a novel oncogenic BRAF fusion gene defines the majority of pilocytic astrocytomas. Cancer Res. 68, 8673\u20138677 (2008).","journal-title":"Cancer Res."},{"key":"2268_CR3","doi-asserted-by":"crossref","DOI":"10.1186\/s40478-020-00902-z","volume":"8","author":"S Ryall","year":"2020","unstructured":"Ryall, S., Tabori, U. & Hawkins, C. Pediatric low-grade glioma in the era of molecular diagnostics. Acta Neuropathol. Commun. 8, 30 (2020).","journal-title":"Acta Neuropathol. Commun."},{"key":"2268_CR4","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1093\/neuonc\/noad078","volume":"25","author":"EC Hardin","year":"2023","unstructured":"Hardin, E. C. et al. LOGGIC Core BioClinical Data Bank: added clinical value of RNA-seq in an international molecular diagnostic registry for pediatric low-grade glioma patients. Neuro. Oncol. 25, 2087\u20132097 (2023).","journal-title":"Neuro. Oncol."},{"key":"2268_CR5","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.ejca.2017.04.019","volume":"81","author":"AK Gnekow","year":"2017","unstructured":"Gnekow, A. K. et al. A European randomised controlled trial of the addition of etoposide to standard vincristine and carboplatin induction as part of an 18-month treatment programme for childhood (\u226416 years) low grade glioma - a final report. Eur. J. Cancer 81, 206\u2013225 (2017).","journal-title":"Eur. J. Cancer"},{"key":"2268_CR6","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1093\/neuonc\/nos202","volume":"14","author":"AK Gnekow","year":"2012","unstructured":"Gnekow, A. K. et al. Long-term follow-up of the multicenter, multidisciplinary treatment study HIT-LGG-1996 for low-grade glioma in children and adolescents of the German Speaking Society of Pediatric Oncology and Hematology. Neuro. Oncol. 14, 1265\u20131284 (2012).","journal-title":"Neuro. Oncol."},{"key":"2268_CR7","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1093\/neuonc\/noq178","volume":"13","author":"GT Armstrong","year":"2011","unstructured":"Armstrong, G. T. et al. Survival and long-term health and cognitive outcomes after low-grade glioma. Neuro. Oncol. 13, 223\u2013234 (2011).","journal-title":"Neuro. Oncol."},{"key":"2268_CR8","doi-asserted-by":"crossref","first-page":"1942","DOI":"10.18632\/oncotarget.27600","volume":"11","author":"T Nicolaides","year":"2020","unstructured":"Nicolaides, T. et al. Phase I study of vemurafenib in children with recurrent or progressive BRAFV600E mutant brain tumors: Pacific Pediatric Neuro-Oncology Consortium study (PNOC-002). Oncotarget 11, 1942\u20131952 (2020).","journal-title":"Oncotarget"},{"key":"2268_CR9","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1093\/neuonc\/now282","volume":"19","author":"A Banerjee","year":"2017","unstructured":"Banerjee, A. et al. A phase I trial of the MEK inhibitor selumetinib (AZD6244) in pediatric patients with recurrent or refractory low-grade glioma: a Pediatric Brain Tumor Consortium (PBTC) study. Neuro Oncol. 19, 1135\u20131144 (2017).","journal-title":"Neuro Oncol."},{"key":"2268_CR10","doi-asserted-by":"publisher","unstructured":"Nobre, L. et al. Outcomes of BRAF V600E pediatric gliomas treated with targeted BRAF inhibition. JCO Precis. Oncol. https:\/\/doi.org\/10.1200\/PO.19.00298 (2020).","DOI":"10.1200\/PO.19.00298"},{"key":"2268_CR11","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1007\/s11060-020-03640-3","volume":"149","author":"F Selt","year":"2020","unstructured":"Selt, F. et al. Response to trametinib treatment in progressive pediatric low-grade glioma patients. J. Neurooncol. 149, 499\u2013510 (2020).","journal-title":"J. Neurooncol."},{"key":"2268_CR12","doi-asserted-by":"crossref","first-page":"7303","DOI":"10.1158\/1078-0432.CCR-19-2177","volume":"25","author":"DR Hargrave","year":"2019","unstructured":"Hargrave, D. R. et al. Efficacy and safety of dabrafenib in pediatric patients with BRAF V600 mutation-positive relapsed or refractory low-grade glioma: results from a phase I\/IIa study. Clin. Cancer Res. 25, 7303\u20137311 (2019).","journal-title":"Clin. Cancer Res."},{"key":"2268_CR13","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1038\/s41591-023-02668-y","volume":"30","author":"LB Kilburn","year":"2024","unstructured":"Kilburn, L. B. et al. The type II RAF inhibitor tovorafenib in relapsed\/refractory pediatric low-grade glioma: the phase 2 FIREFLY-1 trial. Nat. Med. 30, 207\u2013217 (2024).","journal-title":"Nat. Med."},{"key":"2268_CR14","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1056\/NEJMoa2303815","volume":"389","author":"E Bouffet","year":"2023","unstructured":"Bouffet, E. et al. Dabrafenib plus trametinib in pediatric glioma with BRAF V600 mutations. N. Engl. J. Med. 389, 1108\u20131120 (2023).","journal-title":"N. Engl. J. Med."},{"key":"2268_CR15","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.ccell.2017.02.009","volume":"31","author":"DF Quail","year":"2017","unstructured":"Quail, D. F. & Joyce, J. A. The microenvironmental landscape of brain tumors. Cancer Cell 31, 326\u2013341 (2017).","journal-title":"Cancer Cell"},{"key":"2268_CR16","doi-asserted-by":"crossref","first-page":"505","DOI":"10.3171\/2011.4.JNS101172","volume":"115","author":"I Yang","year":"2011","unstructured":"Yang, I., Han, S. J., Sughrue, M. E., Tihan, T. & Parsa, A. T. Immune cell infiltrate differences in pilocytic astrocytoma and glioblastoma: evidence of distinct immunological microenvironments that reflect tumor biology. J. Neurosurg. 115, 505\u2013511 (2011).","journal-title":"J. Neurosurg."},{"key":"2268_CR17","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-019-11493-2","volume":"10","author":"ZJ Reitman","year":"2019","unstructured":"Reitman, Z. J. et al. Mitogenic and progenitor gene programmes in single pilocytic astrocytoma cells. Nat. Commun. 10, 3731 (2019).","journal-title":"Nat. Commun."},{"key":"2268_CR18","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1016\/j.cell.2020.05.007","volume":"181","author":"F Klemm","year":"2020","unstructured":"Klemm, F. et al. Interrogation of the microenvironmental landscape in brain tumors reveals disease-specific alterations of immune cells. Cell 181, 1643\u20131660 (2020).","journal-title":"Cell"},{"key":"2268_CR19","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1093\/neuonc\/noy145","volume":"21","author":"NAP Lieberman","year":"2018","unstructured":"Lieberman, N. A. P. et al. Characterization of the immune microenvironment of diffuse intrinsic pontine glioma: implications for development of immunotherapy. Neuro Oncol. 21, 83\u201394 (2018).","journal-title":"Neuro Oncol."},{"key":"2268_CR20","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-020-18070-y","volume":"11","author":"Y Grabovska","year":"2020","unstructured":"Grabovska, Y. et al. Pediatric pan-central nervous system tumor analysis of immune-cell infiltration identifies correlates of antitumor immunity. Nat. Commun. 11, 4324 (2020).","journal-title":"Nat. Commun."},{"key":"2268_CR21","doi-asserted-by":"crossref","first-page":"1962","DOI":"10.1016\/j.cell.2020.10.044","volume":"183","author":"F Petralia","year":"2020","unstructured":"Petralia, F. et al. Integrated proteogenomic characterization across major histological types of pediatric brain cancer. Cell 183, 1962\u20131985 (2020).","journal-title":"Cell"},{"key":"2268_CR22","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-023-40235-8","volume":"14","author":"R Sigaud","year":"2023","unstructured":"Sigaud, R. et al. MAPK inhibitor sensitivity scores predict sensitivity driven by the immune infiltration in pediatric low-grade gliomas. Nat. Commun. 14, 4533 (2023).","journal-title":"Nat. Commun."},{"key":"2268_CR23","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.neo.2018.11.007","volume":"21","author":"R Chen","year":"2019","unstructured":"Chen, R. et al. KIAA1549-BRAF expression establishes a permissive tumor microenvironment through NF\u03baB-mediated CCL2 production. Neoplasia 21, 52\u201360 (2019).","journal-title":"Neoplasia"},{"key":"2268_CR24","volume":"12","author":"J Chatterjee","year":"2021","unstructured":"Chatterjee, J. et al. Asthma reduces glioma formation by T cell decorin-mediated inhibition of microglia. Nat Commun 12, 7122 (2021).","journal-title":"Nat Commun"},{"key":"2268_CR25","doi-asserted-by":"crossref","first-page":"5647","DOI":"10.1172\/JCI97570","volume":"128","author":"HM Chen","year":"2018","unstructured":"Chen, H. M. et al. Blocking immunoinhibitory receptor LILRB2 reprograms tumor-associated myeloid cells and promotes antitumor immunity. J. Clin. Invest. 128, 5647\u20135662 (2018).","journal-title":"J. Clin. Invest."},{"key":"2268_CR26","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abj1270","volume":"14","author":"MA Stanczak","year":"2022","unstructured":"Stanczak, M. A. et al. Targeting cancer glycosylation repolarizes tumor-associated macrophages allowing effective immune checkpoint blockade. Sci. Transl. Med. 14, eabj1270 (2022).","journal-title":"Sci. Transl. Med."},{"key":"2268_CR27","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1007\/s00262-024-03856-6","volume":"74","author":"C Ma","year":"2025","unstructured":"Ma, C., Li, Y., Li, M., Lv, C. & Tian, Y. Targeting immune checkpoints on myeloid cells: current status and future directions. Cancer Immunol. Immunother. 74, 40 (2025).","journal-title":"Cancer Immunol. Immunother."},{"key":"2268_CR28","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1038\/s43018-023-00598-9","volume":"4","author":"Y Mei","year":"2023","unstructured":"Mei, Y. et al. Siglec-9 acts as an immune-checkpoint molecule on macrophages in glioblastoma, restricting T-cell priming and immunotherapy response. Nat. Cancer 4, 1273\u20131291 (2023).","journal-title":"Nat. Cancer"},{"key":"2268_CR29","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.cell.2019.08.053","volume":"179","author":"M Prinz","year":"2019","unstructured":"Prinz, M., Jung, S. & Priller, J. Microglia biology: one century of evolving concepts. Cell 179, 292\u2013311 (2019).","journal-title":"Cell"},{"key":"2268_CR30","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1146\/annurev-immunol-093019-110159","volume":"39","author":"M Prinz","year":"2021","unstructured":"Prinz, M., Masuda, T., Wheeler, M. A. & Quintana, F. J. Microglia and central nervous system-associated macrophages-from origin to disease modulation. Annu. Rev. Immunol. 39, 251\u2013277 (2021).","journal-title":"Annu. Rev. Immunol."},{"key":"2268_CR31","doi-asserted-by":"crossref","first-page":"3458","DOI":"10.1016\/j.neuron.2022.10.020","volume":"110","author":"RC Paolicelli","year":"2022","unstructured":"Paolicelli, R. C. et al. Microglia states and nomenclature: a field at its crossroads. Neuron 110, 3458\u20133483 (2022).","journal-title":"Neuron"},{"key":"2268_CR32","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1007\/s00432-024-05777-4","volume":"150","author":"R Huang","year":"2024","unstructured":"Huang, R., Kang, T. & Chen, S. The role of tumor-associated macrophages in tumor immune evasion. J. Cancer Res. Clin. Oncol. 150, 238 (2024).","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"2268_CR33","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1038\/ng.2682","volume":"45","author":"DT Jones","year":"2013","unstructured":"Jones, D. T. et al. Recurrent somatic alterations of FGFR1 and NTRK2 in pilocytic astrocytoma. Nat. Genet. 45, 927\u2013932 (2013).","journal-title":"Nat. Genet."},{"key":"2268_CR34","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.neuron.2019.08.028","volume":"104","author":"DH Gutmann","year":"2019","unstructured":"Gutmann, D. H. & Kettenmann, H. Microglia\/brain macrophages as central drivers of brain tumor pathobiology. Neuron 104, 442\u2013449 (2019).","journal-title":"Neuron"},{"key":"2268_CR35","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1073\/pnas.1721434116","volume":"116","author":"G Hutter","year":"2019","unstructured":"Hutter, G. et al. Microglia are effector cells of CD47-SIRP\u03b1 antiphagocytic axis disruption against glioblastoma. Proc. Natl Acad. Sci. USA 116, 997\u20131006 (2019).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"2268_CR36","doi-asserted-by":"crossref","first-page":"6049","DOI":"10.1038\/onc.2017.261","volume":"36","author":"D Yan","year":"2017","unstructured":"Yan, D. et al. Inhibition of colony stimulating factor-1 receptor abrogates microenvironment-mediated therapeutic resistance in gliomas. Oncogene 36, 6049\u20136058 (2017).","journal-title":"Oncogene"},{"key":"2268_CR37","doi-asserted-by":"crossref","DOI":"10.1126\/science.aad3018","volume":"352","author":"DF Quail","year":"2016","unstructured":"Quail, D. F. et al. The tumor microenvironment underlies acquired resistance to CSF-1R inhibition in gliomas. Science 352, aad3018 (2016).","journal-title":"Science"},{"key":"2268_CR38","volume":"3","author":"JA Shapiro","year":"2023","unstructured":"Shapiro, J. A. et al. OpenPBTA: The Open Pediatric Brain Tumor Atlas. Cell Genom. 3, 100340 (2023).","journal-title":"Cell Genom."},{"key":"2268_CR39","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-024-52096-w","volume":"15","author":"AF Andrade","year":"2024","unstructured":"Andrade, A. F. et al. Immune landscape of oncohistone-mutant gliomas reveals diverse myeloid populations and tumor-promoting function. Nat. Commun. 15, 7769 (2024).","journal-title":"Nat. Commun."},{"key":"2268_CR40","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.1016\/j.ccell.2023.09.001","volume":"41","author":"I Ausejo-Mauleon","year":"2023","unstructured":"Ausejo-Mauleon, I. et al. TIM-3 blockade in diffuse intrinsic pontine glioma models promotes tumor regression and antitumor immune memory. Cancer Cell 41, 1911\u20131926 (2023).","journal-title":"Cancer Cell"},{"key":"2268_CR41","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1158\/2326-6066.CIR-23-0418","volume":"12","author":"Y Zhang","year":"2024","unstructured":"Zhang, Y. et al. An NFAT1-C3a-C3aR positive feedback loop in tumor-associated macrophages promotes a glioma stem cell malignant phenotype. Cancer Immunol. Res. 12, 363\u2013376 (2024).","journal-title":"Cancer Immunol. Res."},{"key":"2268_CR42","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1038\/s41586-022-05680-3","volume":"614","author":"E Karimi","year":"2023","unstructured":"Karimi, E. et al. Single-cell spatial immune landscapes of primary and metastatic brain tumours. Nature 614, 555\u2013563 (2023).","journal-title":"Nature"},{"key":"2268_CR43","volume":"11","author":"X Guo","year":"2020","unstructured":"Guo, X. et al. Midkine activation of CD8+ T cells establishes a neuron\u2013immune\u2013cancer axis responsible for low-grade glioma growth. Nat. Commun. 11, 2177 (2020).","journal-title":"Nat. Commun."},{"key":"2268_CR44","volume":"15","author":"AB Levine","year":"2024","unstructured":"Levine, A. B. et al. Immuno-oncologic profiling of pediatric brain tumors reveals major clinical significance of the tumor immune microenvironment. Nat. Commun. 15, 5790 (2024).","journal-title":"Nat. Commun."},{"key":"2268_CR45","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.ccell.2019.10.008","volume":"36","author":"A Leruste","year":"2019","unstructured":"Leruste, A. et al. Clonally expanded T cells reveal immunogenicity of rhabdoid tumors. Cancer Cell 36, 597\u2013612 (2019).","journal-title":"Cancer Cell"},{"key":"2268_CR46","doi-asserted-by":"crossref","first-page":"3209","DOI":"10.1007\/s00381-024-06463-z","volume":"40","author":"R Sigaud","year":"2024","unstructured":"Sigaud, R., Brummer, T., Kocher, D., Milde, T. & Selt, F. MOST wanted: navigating the MAPK-OIS-SASP-tumor microenvironment axis in primary pediatric low-grade glioma and preclinical models. Childs Nerv. Syst. 40, 3209\u20133221 (2024).","journal-title":"Childs Nerv. Syst."},{"key":"2268_CR47","volume":"9","author":"ZJ Xu","year":"2020","unstructured":"Xu, Z. J. et al. The M2 macrophage marker CD206: a novel prognostic indicator for acute myeloid leukemia. Oncoimmunology 9, 1683347 (2020).","journal-title":"Oncoimmunology"},{"key":"2268_CR48","doi-asserted-by":"crossref","first-page":"2370","DOI":"10.1200\/JCO.2017.73.0242","volume":"35","author":"D Sturm","year":"2017","unstructured":"Sturm, D., Pfister, S. M. & Jones, D. T. W. Pediatric gliomas: current concepts on diagnosis, biology, and clinical management. J. Clin. Oncol. 35, 2370\u20132377 (2017).","journal-title":"J. Clin. Oncol."},{"key":"2268_CR49","volume":"4","author":"A de Andrade Costa","year":"2022","unstructured":"de Andrade Costa, A. et al. Immune deconvolution and temporal mapping identifies stromal targets and developmental intervals for abrogating murine low-grade optic glioma formation. Neurooncol. Adv. 4, vdab194 (2022).","journal-title":"Neurooncol. Adv."},{"key":"2268_CR50","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.abi5072","volume":"7","author":"D Moldoveanu","year":"2022","unstructured":"Moldoveanu, D. et al. Spatially mapping the immune landscape of melanoma using imaging mass cytometry. Sci. Immunol. 7, eabi5072 (2022).","journal-title":"Sci. Immunol."},{"key":"2268_CR51","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1038\/s43018-020-0026-6","volume":"1","author":"HR Ali","year":"2020","unstructured":"Ali, H. R. et al. Imaging mass cytometry and multiplatform genomics define the phenogenomic landscape of breast cancer. Nat. Cancer 1, 163\u2013175 (2020).","journal-title":"Nat. Cancer"},{"key":"2268_CR52","volume":"25","author":"Q Guo","year":"2022","unstructured":"Guo, Q. et al. Cancer cell intrinsic TIM-3 induces glioblastoma progression. iScience 25, 105329 (2022).","journal-title":"iScience"},{"key":"2268_CR53","doi-asserted-by":"publisher","unstructured":"Tripathi, S. et al. Pediatric glioma immune profiling identifies TIM3 as a therapeutic target in BRAF fusion pilocytic astrocytoma. J. Clin. Invest. https:\/\/doi.org\/10.1172\/jci177413 (2024).","DOI":"10.1172\/jci177413"},{"key":"2268_CR54","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/j.immuni.2016.01.024","volume":"44","author":"PJR Ebert","year":"2016","unstructured":"Ebert, P. J. R. et al. MAP kinase inhibition promotes T cell and anti-tumor activity in combination with PD-L1 checkpoint blockade. Immunity 44, 609\u2013621 (2016).","journal-title":"Immunity"},{"key":"2268_CR55","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-020-19810-w","volume":"11","author":"A Ribas","year":"2020","unstructured":"Ribas, A. et al. PD-L1 blockade in combination with inhibition of MAPK oncogenic signaling in patients with advanced melanoma. Nat Commun 11, 6262 (2020).","journal-title":"Nat Commun"},{"key":"2268_CR56","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1038\/s41591-022-02181-8","volume":"29","author":"J Tian","year":"2023","unstructured":"Tian, J. et al. Combined PD-1, BRAF and MEK inhibition in BRAFV600E colorectal cancer: a phase 2 trial. Nat. Med. 29, 458\u2013466 (2023).","journal-title":"Nat. Med."},{"key":"2268_CR57","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1038\/s41586-025-08852-z","volume":"641","author":"K Kimura","year":"2025","unstructured":"Kimura, K. et al. Immune checkpoint TIM-3 regulates microglia and Alzheimer\u2019s disease. Nature 641, 718\u2013731 (2025).","journal-title":"Nature"},{"key":"2268_CR58","doi-asserted-by":"crossref","first-page":"3620","DOI":"10.1158\/1078-0432.CCR-20-4746","volume":"27","author":"G Curigliano","year":"2021","unstructured":"Curigliano, G. et al. Phase I\/Ib clinical trial of sabatolimab, an anti-TIM-3 antibody, alone and in combination with spartalizumab, an anti-PD-1 antibody, in advanced solid tumors. Clin. Cancer Res. 27, 3620\u20133629 (2021).","journal-title":"Clin. Cancer Res."},{"key":"2268_CR59","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.3174\/ajnr.A7574","volume":"43","author":"A Trasolini","year":"2022","unstructured":"Trasolini, A. et al. MR imaging of pediatric low-grade gliomas: pretherapeutic differentiation of BRAF V600E mutation, BRAF fusion, and wild-type tumors in patients without neurofibromatosis-1. AJNR Am. J. Neuroradiol. 43, 1196\u20131201 (2022).","journal-title":"AJNR Am. J. Neuroradiol."},{"key":"2268_CR60","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1124\/dmd.114.058339","volume":"42","author":"S Vaidhyanathan","year":"2014","unstructured":"Vaidhyanathan, S., Mittapalli, R. K., Sarkaria, J. N. & Elmquist, W. F. Factors influencing the CNS distribution of a novel MEK-1\/2 inhibitor: implications for combination therapy for melanoma brain metastases. Drug Metab. Dispos. 42, 1292\u20131300 (2014).","journal-title":"Drug Metab. Dispos."},{"key":"2268_CR61","doi-asserted-by":"crossref","first-page":"29","DOI":"10.5455\/jihp.20160623053540","volume":"4","author":"CS Hong","year":"2016","unstructured":"Hong, C. S. et al. Characterization of the blood brain barrier in pediatric central nervous system neoplasms. J. Interdiscip. Histopathol. 4, 29\u201333 (2016).","journal-title":"J. Interdiscip. Histopathol."},{"key":"2268_CR62","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1038\/nature26000","volume":"555","author":"D Capper","year":"2018","unstructured":"Capper, D. et al. DNA methylation-based classification of central nervous system tumours. Nature 555, 469\u2013474 (2018).","journal-title":"Nature"},{"key":"2268_CR63","doi-asserted-by":"publisher","unstructured":"Karimi, E. et al. Machine learning meets classical computer vision for accurate cell identification. Preprint at bioRxiv https:\/\/doi.org\/10.1101\/2022.02.27.482183 (2022).","DOI":"10.1101\/2022.02.27.482183"},{"key":"2268_CR64","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1016\/j.cell.2020.07.005","volume":"182","author":"CM Sch\u00fcrch","year":"2020","unstructured":"Sch\u00fcrch, C. M. et al. Coordinated cellular neighborhoods orchestrate antitumoral immunity at the colorectal cancer invasive front. Cell 182, 1341\u20131359. (2020).","journal-title":"Cell"},{"key":"2268_CR65","doi-asserted-by":"publisher","DOI":"10.1038\/s41596-024-01045-4","author":"S Jin","year":"2024","unstructured":"Jin, S., Plikus, M. V. & Nie, Q. CellChat for systematic analysis of cell-cell communication from single-cell transcriptomics. Nat. Protoc. https:\/\/doi.org\/10.1038\/s41596-024-01045-4 (2024).","journal-title":"Nat. Protoc."},{"key":"2268_CR66","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/s42003-021-02986-2","volume":"5","author":"M Interlandi","year":"2022","unstructured":"Interlandi, M., Kerl, K. & Dugas, M. InterCellar enables interactive analysis and exploration of cell-cell communication in single-cell transcriptomic data. Commun. Biol. 5, 21 (2022).","journal-title":"Commun. Biol."},{"key":"2268_CR67","doi-asserted-by":"publisher","unstructured":"Andrade, A. F. et al. Pediatric-low-grade gliomas dataset. Zenodo https:\/\/doi.org\/10.5281\/zenodo.16614871 (2025).","DOI":"10.5281\/zenodo.16614871"}],"container-title":["Nature Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41590-025-02268-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41590-025-02268-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41590-025-02268-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T22:03:22Z","timestamp":1759183402000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41590-025-02268-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,15]]},"references-count":67,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["2268"],"URL":"https:\/\/doi.org\/10.1038\/s41590-025-02268-7","relation":{},"ISSN":["1529-2908","1529-2916"],"issn-type":[{"value":"1529-2908","type":"print"},{"value":"1529-2916","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,15]]},"assertion":[{"value":"17 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"O.W. and T.M. declare research grant support from Biomed Valley Discoveries and Day One Biopharmaceuticals. The other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}